WO2000025802A1 - Composition pharmaceutique a activite antitumorale et son procede de preparation - Google Patents
Composition pharmaceutique a activite antitumorale et son procede de preparation Download PDFInfo
- Publication number
- WO2000025802A1 WO2000025802A1 PCT/KR1999/000659 KR9900659W WO0025802A1 WO 2000025802 A1 WO2000025802 A1 WO 2000025802A1 KR 9900659 W KR9900659 W KR 9900659W WO 0025802 A1 WO0025802 A1 WO 0025802A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- powdered
- radix
- lyophilizing
- filtering
- auxiliaries
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- composition having antitumor activity and process for the preparation thereof
- the present invention relates to a pharmaceutical composition having antitumor activity which contains herb medicines as the main ingredients, and process for the preparation thereof.
- the inventor had invented a pharmaceutical composition of herb medicines having antitumor activity and process for the preparation thereof, and the invention was granted the Korean patent No. 72982.
- the above-mentioned patent discloses a pharmaceutical composition containing PulsatiUae Radix ( Pulsatilla koreana Nakai, P. cernua, P. danurica, P. ratensis, Chinese PulsatiUae, Mongolian PulsatiUae ) and/or Clematis Chinensis Osbeclo ( so called, Chinese clematis) as the main ingredients, and optionally Ulmaceae Cortex, Armeniacae Semen, Ginseng Radix and Glycyrrhizae Radix and process for the preparation thereof.
- PulsatiUae Radix Pulsatilla koreana Nakai, P. cernua, P. danurica, P. ratensis, Chinese PulsatiUae, Mongolian PulsatiUae
- Clematis Chinensis Osbeclo so called, Chinese clematis
- PulsatiUae species are grown wild all over the world, and the PulsatiUae Radix has been used as an antiphlogistic agent, astringent and hemostatic agent and thus for the treatment of dysentery in Korea. It is known that the PulsatiUae Radix contains anemonin, protoanemonin and saponin. Protoanemonin is the precursor of anemonin, and both may be dissolved in water, alcohol, chloroform, methylene chloride and the like. Clematis Radix contains anemonin, anemonol and saponin. It has been used as an agent for gout, diuretic agent and agent for difficult menstruum.
- Ulmaceae Cortex contains mucin and tannin, and has been used as a lenitive and adhesive.
- Ginseng Radix has been known from ancient times as a admirelous medicine in the Far East. It has been used as a tonic, agent for acute gastritis and agent for various bleeding diseases. Recently, it is reported that Ginseng Radix has antitumor activity and contains Ginseng alkaloids, Ginseng saponins, essence oil, etc.
- Glycyrrhizae Radix contains glycyrrhizin, liquiritin, licoricidin and liquiritoside and has been used as a cough remedy, expectorant, diaphoretic and agent for gastritis.
- the above invention by the present inventor relates to a pharmaceutical composition having excellent antitumor activity and containing extract or powder of PulsatiUae Radix and/or Clematis Radix as the main ingredients, and optionally extract or powder of Ulmaceae Cortex, Armeniacae Semen, Ginseng Radix and Glycyrrhizae Radix.
- the composition may be prepared by drying and finely powdering each herb ingredients ; by extracting the herb ingredients in a solvent selected from water, lower alcohol, chloroform, methylene chloride and the others which may dissolve the effective ingredients of the herbs at the temperature of 0 ° C - the boiling point of the used solvent for 30 minutes to 24 hours and then vaporizing the used solvent to give the extract ; or dissolving said extract in water, alcohol or the mixed solvent thereof.
- a solvent selected from water, lower alcohol, chloroform, methylene chloride and the others which may dissolve the effective ingredients of the herbs at the temperature of 0 ° C - the boiling point of the used solvent for 30 minutes to 24 hours and then vaporizing the used solvent to give the extract ; or dissolving said extract in water, alcohol or the mixed solvent thereof.
- each herb may be extracted independently or two or more herbs may be extracted together.
- the extract is powdered and formulated to a pharmaceutical preparation by using vehicles such as lactose, various starches, sucrose, mannitol, sorbitol and inorganic salts such as calcium phosphate, calcium sulfate, aluminiun silicate and calcium carbonate ; binders such as sucrose, glucose, starch, gelatin, carboxymethylcelluose, methylcellulose, gum arabic, gum tragacanth, ethylcellulose, sodium alginate, hydroxypropylmethylcellulose, polyvinylpyrrolidone and soluble cellulose ; disintegrators such as starch, carboxymethylcellulose, methylcellulose and crystalline cellulose ; lubricants such as magnesium stearate and calcium stearate ; wetting agents such as glycerine, propylene glycol and sorbitol I preservatives such as sodium benzoate, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, benzalkonium chloride
- the inventor has continued intensive study to improve the antitumor composition and found that the composition by the prior invention is very unstable for preservation whereby it may easily lose its pharmaceutical effects in 3-6 months.
- an object of the present invention is to provide an improved pharmaceutical composition which is stable and maintains its pharmaceutical efficacy even if it is preserved for several years, comprising lyophilized powder of PulsatiUae Radix, Ulmaceae Cortex, or mixture thereof as the main herb ingredients, and optionally one or more auxiliary herb ingredients selected from Ginseng Radix and Glycyrrhizae Radix, and conventional auxiliaries such as used in the prior invention ( Korean patent No. 72982 ).
- the inventor has completed the present invention by discovering that herb ingredients should be extracted in a solvent at the temperature of below 60 °C and promptly lyophilized in order to maintain efficacy of the composition and preserve it for a long time.
- the pharmaceutical composition in the present invention comprises as the main active herb ingredients 0-100wt of PulsatiUae Radix and 0-100wt% of Ulmaceae Cortex, and optionally as the auxiliary herb ingredients 0 ⁇ 70wt% of Ginseng Radix and 0-70wt% of Glycyrrhizae
- the content of PulsatiUae Radix and/or Ulmaceae Cortex is over 30wt%.
- the pharmaceutical composition having antitumor activity according to the present invention may be prepared by : extracting powdered PulsatiUae Radix and/or powdered Ulmaceae cortex, and optionally one ore more herb ingredients selected from powdered Ginseng Radix and powdered Glycyrrhizae Radix in a solvent at the temperature of below 60 ° C, filtering and lyophilizing the extract, and admixing the lyophilized powder with conventional auxiliaries, alternatively admixing the above extracted solution with auxiliaries, then filtering and lyophilizing the mixture, and then formulating the lyophilized powder to a pharmaceutical preparation by a conventional method used in the pharmaceutics.
- composition is to be used by injection, before lyophilization, it is advisable that the extracted solution is premixed with conventional auxiliaries including a preservative such as methylparaben, ethylparaben and propylparaben, an isotonic agent such as sodium chloride and an indolent agent such as benzylalcohol.
- a preservative such as methylparaben, ethylparaben and propylparaben
- an isotonic agent such as sodium chloride
- an indolent agent such as benzylalcohol.
- the extracted solution of the herb ingredients is lyophilized and then the lyophilized powder is admixed with conventional auxiliaries such as used in the invention of the Korean patent No. 72982 by a conventional method in the pharmaceutics to give a pharmaceutical preparation.
- the solvent for extraction of herb ingredients may include water, lower alcohol, acetone, ethyl acetate, hexane and mixtures thereof.
- the herb ingredients are extracted in a solvent at the temperature of below 60 °C , and immediately lyophilized.
- the lyophilized powder of the herb ingredients as above may be filled into a vial and it may be applied by adding distilled water for injection thereinto, or the lyophilized powder may be formulated to a form of capsule, tablet or ointment by a conventional method in the pharmaceutics.
- About lOOmg to 5g of the present composition on the basis of the lyophilized powder may be administered in a day, once a week to 1 - 3 times for a day.
- the dose of the composition may be varied in consideration of sex, age, condition of disease, etc. of the patients
- Comparative example 1 6.26g of powdered PulsatiUae Radix was added into 90ml of purified water and the mixture was warmed to 60 ° C and stirred for 60 minutes, and then centrifuged at 3,500 rpm for 30 minutes. 50ml of the centrifuged solution was filtered in a sterilized room at below 60 °C . The resulting solution was made to isotonic solution by adding NaCl under the aseptic condition, then sterile-filtered once again and divided to each 2.5 ml of the solution in an ampoule of 3ml under the aseptic condition, and sealed to obtain injection ampoules.
- Comparative example 2 4g of powdered PulsatiUae Radix, 2g of powdered Ulmaceae cortex, 2g of powdered Ginseng Radix and lg of powdered Glycyrrhizae Radix were added to 90ml of purified water and the mixture was stirred for 60 minutes at about 80 ° C by adding purified water corresponding to the water distilled off. The resulting solution was cooled to room temperature, centrifuged with 3,500 rpm for 30 minutes to obtain 46ml of the extracted solution. NaCl was added to the extract to obtain isotonic solution. The isotonic solution was filtered by a conventional method in a sterilized room, sterile- filtered and divided into each 2ml of the solution in an ampoule of 3ml, sealed and stored in a refrigerator.
- Example 2 6g of powdered PulsatiUae Radix, 4g of powdered Ulmaceae cortex and 0.9g of powdered Glycyrrhizae Radix were added to 100ml of distilled water and extracted for 60 minutes at a temperature of below 60 ° C with stirring. After the extracted solution was centrifuged with 5000 rpm, 900mg of NaCl as an isotonic agent and 160mg of methyl paraoxybenzoate as a preservative were added thereto. The resulting mixture was sterile-filtered in a sterilized room, divided into 20 vials of 5ml, promptly lyophilized at below -40 °C , sealed to obtain injectable powder.
- Example 4 60g of powdered PulsatiUae Radix, 40g of powdered Ulmaceae cortex and 9g of powdered Glycyrrhizae Radix were added to 1000ml of distilled water and extracted with stirring for 60 minutes at the temperature of below 60 ° C with adding distilled water corresponding to the water distilled off. The extracted solution was centrifuged with 5000 rpm and promptly lyophilized at below -40 °C to give 38,150mg of the lyophilized powder.
- Example 5 60g of powdered PulsatiUae Radix, 60g of powdered Ulmaceae cortex and 9g of powdered Glycyrrhizae Radix were added to 1000ml of 50%(v/v) ethanol and extracted for 60 minutes at the temperature of 50 - 60 ° C with adding the alcohol corresponding to that distilled off. The 5 extracted solution was centrifuged with 5000 rpm and promptly lyophilized at below -40 ° C to give 45,150mg of the lyophilized powder.
- Example 6 60g of powdered PulsatiUae Radix, 30g of powdered Ginseng Radix
- Example 8 lOg of powdered Ulmaceae cortex was added to 100ml of 50%(v/v) ethanol and extracted for 60 minutes at the temperature of below 60 ° C with stirring. The extracted solution was centrifuged with 5000 rpm, and 5 900mg of NaCl as an isotonic agent and thereto 160mg of methyl paraoxybenzoate as a preservative were added. The resulting mixture was sterile-filtered in a sterilized room, divided into 20 vials of 5ml, promptly lyophilized at below -40 ° C , sealed to obtain injectable powder.
- 60g of powdered PulsatiUae Radix, 60g of powdered Ulmaceae cortex and 9g of powdered Glycyrrhizae Radix were added to 1000ml of hexane and extracted for 90 minutes at the temperature of below 60 ° C with stirring and adding the hexane corresponding to the amount distilled off. 5
- the extracted solution was centrifuged with 5000 rpm and the resulting solution was promptly lyophilized at below -40 ° C to obtain the lyophilized powder.
- the lyophilized powder obtained by the example 1 was administered to 8 rats of 234-276g, whereby the LD50 was 800mg/kg.
- 0.1ml of suspension of Sarcoma 180 cellsQxlO 6 cells was injected (s.c.) into 30 rats of about 25g to develop tumors.
- 0.15ml of injection prepared by dissolving the injectable powder of the example 1 in 5ml of distilled water for injection was injected (s.c.) to 10 rats once a day and 0.15ml of injection of the comparative example 1 was injected (s.c.) to another 10 rats once a day.
- 0.15ml of physiological saline solution was injected to the other 10 rats for 10 days as the control group.
- Each 9 rats of the groups which were treated with the injection of the example 1 and the comparative example 1 were cured by injection for 15 days, and each 1 rat of the groups died at the 16th day, while 10 rats of the control group died all off beginning at the 10th day till to the 15th day.
- Antitumor effect 0.1ml of suspension of Sarcoma 180 cellsQxlO 6 cells) was injected(s.c) into 30 rats of about 25g to develop tumors. After 6 days, 0.15ml of injection prepared by dissolving the injectable powder of the example 1 in 5ml of distilled water for injection was injected (s.c.) to 10 rats ( group 1 ) once a day, and 0.15ml of injection of the comparative example 1 preserved for 6 months in a refrigerator was injected (s.c.) to another 10 rats ( group 2 ) once a day, and 0.15ml of physiological saline solution was injected to the other 10 rats for 10 days as the control group ( group 3 ),
- 0.1ml of suspension of Sarcoma 180 cellsQxlO 6 cells was injected (s.c.) into 48 rats of about 25g to develop tumors.
- 0.15ml of sample injection prepared by dissolving the injectable powder of the example 3 in 5ml of distilled water for injection was injected (s.c.) to 7 rats once a day ( group 1 )
- each 0.15ml of the sample injection of the example 3 was injected (s.c.) to another 7 rats twice a day( group 2 )
- 0.15ml of sample injection of the comparative example 1 was injected (s.c.) to another 7 rats once a day ( group 3 )
- each 0.15ml of sample injection of the comparative example 1 was injected (s.c.) to another 7 rats twice a day ( group 4 )
- 0.15ml of injection of the comparative example 1 which was preserved for 3 months in a refrigerator was injected (s.c.) to another 7 rats once a day ( group 5 ), each
- 1 rat died at the 15th day of carcinogenesis 1 rat died at the 17th day, 1 rat died at the 18th day, 1 rat died at the 19th day, and 1 rat died at the 21th day, while 2 rats were cured by injection for 21 days.
- Diagnosis General hospital affiliated to the Youngnam University in Taegu on May 7, 1992.
- Medication 12ml of the injection was injected (i.v.) once a day for 4 days, while each 10ml of the injection was injected into the protruded tumor twice a day for 8 days ( totally 15 times ), and then no treatment of injection was performed for 25 days. After that, medication was repeated by i.v. injection and direct injection into the protruded tumor as the same method above, whereby the tumor disappeared completely. After 5 years, the General hospital affiliated to the Youngnam University and the General hospital affiliated to the Chungnam University decided that the patient was completely cured.
- Medication 10ml of the injection was injected (i.v.) once a day for 4 days, and then no treatment was performed for 3 weeks. Same medication was repeated for 7 months of the above period, whereby the tumor and related symptoms disappeared completely. After 6 years, the General hospital affiliated to the Yonsei University and the General hospital affiliated to the Chungnam University decided that the patient was completely cured.
- Experiment 7 Clinical Test on a volunteer by administration of the injection prepared by dissolving the injectable powder of the example 2 in distilled water for injection.
- Medication 12ml of the injection was injected (i.v.) once a day for 4 days, and then no treatment was performed for 3 weeks. Same medication was repeated for 7 months of the above period, whereby the residual tumor disappeared completely. After 6 years from the medication, the Goshin Medical Center in Pusam and the General hospital affiliated to the Chungnam University decided that the patient was completely cured.
- Subject Name : PARK, Ju-Sang ( 45 years old at the treatment, male) Address : 15/2, 387-3, Bugok 1-dong, Kumjeong-gu, Pusan, Korea kind of disease : Progressed stomach cancer. Feeling heavy on the stomach, Dyspepsia and Weight loss.
- Medication 12ml of the injection was injected (i.v.) once a day for 4 days, and simultaneously each 173mg of the sample was taken internally four times a day.
- the i.v. injection was perform in such a manner that the injection was i.v. injected for 4 days and then no injection was made for 4 weeks, while the internal administration was continued. As the result, the symptoms disappeared completely and he was ascertained to be normal by the biopsy. After 6 years, the Goshin Medical Center decided that the patient was completely cured.
- Diagnosis Goshin Medical Center in Pusan on April 8, 1994. Period of medication : From May 31, 1994 to December 30, 1994
- Medication 9ml of the injection was injected (i.v.) once a day for 4 days, and simultaneously 4ml of the sample was injected directly into the residual tumor in liver once a day for 3 days and then for 3 weeks no treatment was performed. The same medication was performed three times, and then from the 4th cycle of medication, only i.v. injection was performed, whereby the residual tumor disappeared completely. After 3 years, the Goshin Medical Center and the Hospital affiliated to Chungnam University decided that the patient was completely cured.
- Samples of the lyophilized power for injection prepared by the examples according to the present invention were preserved for 2 years and then dissolved in distilled water for injection. The resulting solution was transparent light brown and no precipitation settled.
- Stability test 2 Samples of injection prepared by the comparative example 2 were stored for 1 month, 2 months and 3 months respectively. In the resulting solutions precipitate settled in 1 month and in three months the solutions was turbid whereby it was unable to be used for injection.
- the antitumor compositions by the prior invention are sensitive to moisture, and even if stored in a refrigerator, they are easily deteriorated and efficacy thereof is severely decreased, whereby they cannot be preserved for a long time and then they cannot be used as a medicine.
- compositions which are prepared by extracting the herb ingredients at the temperature of below 60 °C and after extraction immediately lyophilizing the extract have no change in quality and efficacy thereof after long preservation, whereby they may be used safely.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0101256A HUP0101256A3 (en) | 1998-11-03 | 1999-11-03 | Pharmaceutical composition having antitumor activity and process for the preparation thereof |
JP2000579242A JP2002528511A (ja) | 1998-11-03 | 1999-11-03 | 生薬を主成分とした安定化された抗ガン剤組成物及びその製造方法 |
AU10804/00A AU1080400A (en) | 1998-11-03 | 1999-11-03 | Pharmaceutical composition having antitumor activity and process for the preparation thereof |
CA002317113A CA2317113A1 (fr) | 1998-11-03 | 1999-11-03 | Composition pharmaceutique a activite antitumorale et son procede de preparation |
BR9907168-1A BR9907168A (pt) | 1998-11-03 | 1999-11-03 | "composição farmacêutica anti-tumoral e processo para a preparação de uma composição farmacêutica anti-tumoral" |
EP99954463A EP1044011A1 (fr) | 1998-11-03 | 1999-11-03 | Composition pharmaceutique a activite antitumorale et son procede de preparation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR19980047025 | 1998-11-03 | ||
KR1998/47025 | 1998-11-03 | ||
KR1019980048277A KR100312622B1 (ko) | 1998-11-03 | 1998-11-11 | 생약을주성분으로한안정화된항암제조성물및그제조방법 |
KR1998/48277 | 1998-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000025802A1 true WO2000025802A1 (fr) | 2000-05-11 |
Family
ID=26634281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR1999/000659 WO2000025802A1 (fr) | 1998-11-03 | 1999-11-03 | Composition pharmaceutique a activite antitumorale et son procede de preparation |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1044011A1 (fr) |
JP (1) | JP2002528511A (fr) |
KR (1) | KR100312622B1 (fr) |
CN (1) | CN1179729C (fr) |
AU (1) | AU1080400A (fr) |
BR (1) | BR9907168A (fr) |
CA (1) | CA2317113A1 (fr) |
HU (1) | HUP0101256A3 (fr) |
PL (1) | PL341650A1 (fr) |
RU (1) | RU2201759C2 (fr) |
WO (1) | WO2000025802A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004051641A (ja) * | 2002-07-22 | 2004-02-19 | Kim Song Bae | ヘデラゲニン3−O−α−L−ラムノピラノシル(1→2)−[β−D−グルコピラノシル(1→4)]−α−L−アラビノピラノシド、及びそれを含有する白頭翁抽出物の固形腫瘍治療剤としての用途 |
US6812258B2 (en) | 1998-12-07 | 2004-11-02 | Ecosmart Technologies, Inc. | Cancer treatment composition and method using natural plant essential oils |
JP2005511642A (ja) * | 2001-11-30 | 2005-04-28 | ファイザー・プロダクツ・インク | セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用 |
WO2006016747A1 (fr) * | 2004-07-30 | 2006-02-16 | Song-Bae Kim | Procede permettant d'ameliorer l'effet anticancereux de radix pulsatillae et composition preparee au moyen de ce procede |
CN111466484A (zh) * | 2020-04-15 | 2020-07-31 | 四川中地油科技有限公司 | 一种黑水虻软腐病防治复合配方及其制作方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100515206B1 (ko) * | 2002-09-23 | 2005-09-16 | 김종석 | 백두옹 추출물을 주성분으로 함유하는 미백 화장용 조성물 |
MD2231C2 (ro) * | 2003-03-05 | 2004-02-29 | Ион КАЛМЫК | Compozitie pentru tratamentul patologiilor oncologice |
JP4892833B2 (ja) * | 2004-12-17 | 2012-03-07 | 大正製薬株式会社 | 脂肪吸収抑制剤 |
JP2012246311A (ja) * | 2012-09-05 | 2012-12-13 | Sk Chemicals Co Ltd | 脳機能改善効果を有するオキナグサ抽出物 |
RU2759382C2 (ru) | 2017-07-07 | 2021-11-12 | Ци Лю | Препарат для инъекций на основе сапонина b4 pulsatilla |
CN107468747A (zh) * | 2017-10-10 | 2017-12-15 | 刘建明 | 一种有利于抗癌、防癌的人参组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0416502A1 (fr) * | 1989-09-04 | 1991-03-13 | Song Bae Kim | Composition pharmaceutique ayant une activité antitumorale et préparation pour sa fabrication |
WO1998024795A1 (fr) * | 1996-12-05 | 1998-06-11 | Song Bae Kim | Nouveau compose glycoside triterpenique, son procede de fabrication et composition anticancereuse le contenant |
-
1998
- 1998-11-11 KR KR1019980048277A patent/KR100312622B1/ko not_active IP Right Cessation
-
1999
- 1999-11-03 RU RU2000120474/14A patent/RU2201759C2/ru not_active IP Right Cessation
- 1999-11-03 WO PCT/KR1999/000659 patent/WO2000025802A1/fr not_active Application Discontinuation
- 1999-11-03 BR BR9907168-1A patent/BR9907168A/pt not_active IP Right Cessation
- 1999-11-03 JP JP2000579242A patent/JP2002528511A/ja active Pending
- 1999-11-03 CA CA002317113A patent/CA2317113A1/fr not_active Abandoned
- 1999-11-03 CN CNB998019763A patent/CN1179729C/zh not_active Expired - Fee Related
- 1999-11-03 AU AU10804/00A patent/AU1080400A/en not_active Abandoned
- 1999-11-03 PL PL99341650A patent/PL341650A1/xx not_active Application Discontinuation
- 1999-11-03 EP EP99954463A patent/EP1044011A1/fr not_active Withdrawn
- 1999-11-03 HU HU0101256A patent/HUP0101256A3/hu unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0416502A1 (fr) * | 1989-09-04 | 1991-03-13 | Song Bae Kim | Composition pharmaceutique ayant une activité antitumorale et préparation pour sa fabrication |
WO1998024795A1 (fr) * | 1996-12-05 | 1998-06-11 | Song Bae Kim | Nouveau compose glycoside triterpenique, son procede de fabrication et composition anticancereuse le contenant |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812258B2 (en) | 1998-12-07 | 2004-11-02 | Ecosmart Technologies, Inc. | Cancer treatment composition and method using natural plant essential oils |
EP1137426B1 (fr) * | 1998-12-07 | 2005-10-26 | Ecosmart Technologies, Inc. | Utilisation d'huiles essentielles vegetales naturelles pour le traitement du cancer du sein |
JP2005511642A (ja) * | 2001-11-30 | 2005-04-28 | ファイザー・プロダクツ・インク | セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用 |
JP4689959B2 (ja) * | 2001-11-30 | 2011-06-01 | ファイザー・プロダクツ・インク | セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用 |
JP2004051641A (ja) * | 2002-07-22 | 2004-02-19 | Kim Song Bae | ヘデラゲニン3−O−α−L−ラムノピラノシル(1→2)−[β−D−グルコピラノシル(1→4)]−α−L−アラビノピラノシド、及びそれを含有する白頭翁抽出物の固形腫瘍治療剤としての用途 |
JP4642330B2 (ja) * | 2002-07-22 | 2011-03-02 | ソンベ キム | ヘデラゲニン3−O−α−L−ラムノピラノシル(1→2)−[β−D−グルコピラノシル(1→4)]−α−L−アラビノピラノシド、及びそれを含有する白頭翁抽出物の固形腫瘍治療剤としての用途 |
WO2006016747A1 (fr) * | 2004-07-30 | 2006-02-16 | Song-Bae Kim | Procede permettant d'ameliorer l'effet anticancereux de radix pulsatillae et composition preparee au moyen de ce procede |
CN111466484A (zh) * | 2020-04-15 | 2020-07-31 | 四川中地油科技有限公司 | 一种黑水虻软腐病防治复合配方及其制作方法 |
Also Published As
Publication number | Publication date |
---|---|
AU1080400A (en) | 2000-05-22 |
HUP0101256A2 (hu) | 2004-05-28 |
RU2201759C2 (ru) | 2003-04-10 |
JP2002528511A (ja) | 2002-09-03 |
EP1044011A1 (fr) | 2000-10-18 |
BR9907168A (pt) | 2000-10-17 |
CN1179729C (zh) | 2004-12-15 |
CN1287490A (zh) | 2001-03-14 |
CA2317113A1 (fr) | 2000-05-11 |
HUP0101256A3 (en) | 2006-02-28 |
KR20000031989A (ko) | 2000-06-05 |
KR100312622B1 (ko) | 2002-02-28 |
PL341650A1 (en) | 2001-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102193363B1 (ko) | 신규 살비아놀산 화합물 t, 그 제조 방법, 및 용도 | |
WO1999047148A1 (fr) | Compositions a base de feuilles de ginkgo biloba, leurs procedes de preparation et leurs applications | |
KR940000234B1 (ko) | 신규 항암작용을 가지는 약학적 제제 및 제조방법 | |
EP1044011A1 (fr) | Composition pharmaceutique a activite antitumorale et son procede de preparation | |
JP2009542634A (ja) | 絡石藤抽出物を含有する炎症性疾患の予防及び治療用医薬組成物 | |
GB2476070A (en) | Subcritical water extraction of Hawthorn Crategus monogyna, Pueraria lobata and Centella asiatica | |
US4460578A (en) | Pharmaceutical composition for topical use based on a total extract of Hedysarum fructescens willd | |
CN1679698A (zh) | 一种由三七、川芎制成的治疗心脑血管疾病的药物制剂及其制备方法 | |
JPH05502457A (ja) | カバーカバ抽出物、これらの製造プロセスおよび使用 | |
JP5231244B2 (ja) | 胃炎または胃潰瘍の予防及び治療に有用なモクベツシ抽出物及びこれから分離されたモモルディカ・サポニンi | |
CN1679701A (zh) | 一种由三七、红花制成的治疗心脑血管疾病的药物制剂及其制备方法 | |
TWI527587B (zh) | 苧麻屬植物之萃取物用於製備治療肝臟纖維化之藥物的用途 | |
JPS625126B2 (fr) | ||
MXPA00006377A (es) | Composicion farmaceutica que tiene actividad antitumoral y proceso para la preparacion de la misma | |
JP2009520020A5 (fr) | ||
CN114736182B (zh) | 一种抗心肌缺血再灌注损伤的化合物和傣药组合物及其应用 | |
CN1312169C (zh) | 一种新的龙胆有效部位的制备及其应用 | |
CN109078072A (zh) | 一种用于预防冠心病的口服制剂 | |
CN112472765B (zh) | 一种清热八味提取物的制备方法 | |
CN108743654B (zh) | 一种用于治疗缺血性心脏病的中药组合物及其制备方法和应用 | |
CN111568935B (zh) | 赤苍藤提取物在制备抗肿瘤药物中的应用 | |
CN102379864A (zh) | 一种治疗血管栓塞性疾病的复方丹参素注射剂及其制备工艺 | |
KR100213667B1 (ko) | 항당뇨 효과를 가지는 조성물 | |
KR101064503B1 (ko) | 단삼 추출물의 속효성 고체 분산체, 이를 함유한 경구용 제제 및 이들의 제조방법 | |
KR20220142155A (ko) | 숙지황의 히드록시메틸푸르푸날 및 히드록시메틸푸르푸날 포접체를 함유하는 비경구적 투여 제제 조성물을 제조하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99801976.3 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 10804 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2000/00060/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999954463 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/006377 Country of ref document: MX Ref document number: 10804/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2317113 Country of ref document: CA Ref document number: 2317113 Country of ref document: CA Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09582877 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999954463 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999954463 Country of ref document: EP |